WO2018097570A3 - Formulation pharmaceutique comprenant de la l-proline de dapagliflozine - Google Patents

Formulation pharmaceutique comprenant de la l-proline de dapagliflozine Download PDF

Info

Publication number
WO2018097570A3
WO2018097570A3 PCT/KR2017/013243 KR2017013243W WO2018097570A3 WO 2018097570 A3 WO2018097570 A3 WO 2018097570A3 KR 2017013243 W KR2017013243 W KR 2017013243W WO 2018097570 A3 WO2018097570 A3 WO 2018097570A3
Authority
WO
WIPO (PCT)
Prior art keywords
dapagliflozin
proline
pharmaceutical formulation
present
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/013243
Other languages
English (en)
Korean (ko)
Other versions
WO2018097570A2 (fr
Inventor
권세호
김재호
김진철
김용일
박재현
우종수
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of WO2018097570A2 publication Critical patent/WO2018097570A2/fr
Publication of WO2018097570A3 publication Critical patent/WO2018097570A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique comprenant de la L-proline de dapagliflozine. La formulation pharmaceutique comprenant de la L-proline de dapagliflozine selon la présente invention présente d'excellentes propriétés de dissolution d'agents actifs et une uniformité de contenu élevée. Par conséquent, la formulation pharmaceutique comprenant de la L-proline de dapagliflozine selon la présente invention peut être utilisée en tant qu'agent préventif ou thérapeutique, qui a une excellente qualité et une excellente biodisponibilité, pour le diabète, les maladies associées au diabète et les complications diabétiques.
PCT/KR2017/013243 2016-11-24 2017-11-21 Formulation pharmaceutique comprenant de la l-proline de dapagliflozine Ceased WO2018097570A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0157550 2016-11-24
KR1020160157550A KR20180058510A (ko) 2016-11-24 2016-11-24 다파글리플로진 l-프롤린을 포함하는 약제학적 제제

Publications (2)

Publication Number Publication Date
WO2018097570A2 WO2018097570A2 (fr) 2018-05-31
WO2018097570A3 true WO2018097570A3 (fr) 2018-08-09

Family

ID=62195318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/013243 Ceased WO2018097570A2 (fr) 2016-11-24 2017-11-21 Formulation pharmaceutique comprenant de la l-proline de dapagliflozine

Country Status (2)

Country Link
KR (1) KR20180058510A (fr)
WO (1) WO2018097570A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110922372A (zh) * 2019-11-04 2020-03-27 天津大学 达格列净的氨基酸共晶物及其制备方法
KR102838283B1 (ko) * 2020-07-10 2025-07-25 한미약품 주식회사 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
MX2023004218A (es) * 2020-10-13 2023-04-21 Lg Chemical Ltd Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma.
US20240207242A1 (en) * 2021-04-14 2024-06-27 Lg Chem, Ltd. Pharmaceutical composition comprising sphingosine-1-phosphate receptor agonist with controlled particle size
CN115343198A (zh) * 2022-08-17 2022-11-15 扬子江药业集团上海海尼药业有限公司 达格列净原料药的粒径测定方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090023643A (ko) * 2006-06-28 2009-03-05 브리스톨-마이어스 스큅 컴퍼니 당뇨병 치료를 위한 ｓｇｌｔ2 억제제로서의, (1ｓ)-1,5-안히드로-1-ｃ-(3-((페닐)메틸)페닐)-ｄ-글루시톨 유도체와 아미노산의 결정질 용매화물 및 복합체
KR20110114658A (ko) * 2009-02-13 2011-10-19 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 임의로 ｓｇｌｔ２ 억제제를 포함하는 약제학적 조성물 및 이의 용도
US20140343010A1 (en) * 2013-04-29 2014-11-20 Mapi Pharma Ltd. Co-crystals of dapagliflozin
WO2015117538A1 (fr) * 2014-02-10 2015-08-13 江苏豪森药业股份有限公司 Nouvelle forme cristalline de la dapagliflozine et son procédé de préparation
KR20160034348A (ko) * 2013-07-22 2016-03-29 산도즈 아게 무정형 다파글리플로진을 함유하는 제제
WO2016147197A1 (fr) * 2015-03-17 2016-09-22 Harman Finochem Limited Nouveau procédé de préparation de (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-éthoxybenzyl)phényl]-6-(hydroxyméthyl)tétrahydro-2h-pyran-3,4,5-triol et sa forme amorphe
KR20160121190A (ko) * 2015-04-10 2016-10-19 제이더블유중외제약 주식회사 아나글립틴 또는 이의 약학적으로 허용 가능한 염 및 메트포르민 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 및 그의 제조 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090023643A (ko) * 2006-06-28 2009-03-05 브리스톨-마이어스 스큅 컴퍼니 당뇨병 치료를 위한 ｓｇｌｔ2 억제제로서의, (1ｓ)-1,5-안히드로-1-ｃ-(3-((페닐)메틸)페닐)-ｄ-글루시톨 유도체와 아미노산의 결정질 용매화물 및 복합체
KR20110114658A (ko) * 2009-02-13 2011-10-19 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 임의로 ｓｇｌｔ２ 억제제를 포함하는 약제학적 조성물 및 이의 용도
US20140343010A1 (en) * 2013-04-29 2014-11-20 Mapi Pharma Ltd. Co-crystals of dapagliflozin
KR20160034348A (ko) * 2013-07-22 2016-03-29 산도즈 아게 무정형 다파글리플로진을 함유하는 제제
WO2015117538A1 (fr) * 2014-02-10 2015-08-13 江苏豪森药业股份有限公司 Nouvelle forme cristalline de la dapagliflozine et son procédé de préparation
WO2016147197A1 (fr) * 2015-03-17 2016-09-22 Harman Finochem Limited Nouveau procédé de préparation de (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-éthoxybenzyl)phényl]-6-(hydroxyméthyl)tétrahydro-2h-pyran-3,4,5-triol et sa forme amorphe
KR20160121190A (ko) * 2015-04-10 2016-10-19 제이더블유중외제약 주식회사 아나글립틴 또는 이의 약학적으로 허용 가능한 염 및 메트포르민 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
WO2018097570A2 (fr) 2018-05-31
KR20180058510A (ko) 2018-06-01

Similar Documents

Publication Publication Date Title
WO2018097570A3 (fr) Formulation pharmaceutique comprenant de la l-proline de dapagliflozine
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
MX2024008464A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12018500690A1 (en) Novel insulin analogs and use thereof
PH12020500134A1 (en) Dihydrooxadiazinones
EP3575314A3 (fr) Dérivés de glucagon
EP3176163A4 (fr) Nouveau derive d'indene, son procede de preparation, et composition pharmaceutique pour la prevention ou le traitement de maladies retiniennes en contenant comme principe actif
CR20190523A (es) Compuesto de insulina acilada
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
PH12019500778A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
MX2022009682A (es) Composicion farmaceutica que contiene regorafenib y un agente estabilizante.
WO2018005794A3 (fr) Nouveaux agonistes de tgr5 non systémiques
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
IL268224A (en) A pharmaceutical compound for the prevention and treatment of pancreatic cancer, containing GOSSYPOL and PHENFORMIN as active ingredients
EP4338751A3 (fr) Médicament comprenant une combinaison de sépiétart et d'inhibiteur de protéine kinase contenant une superhélice associée à rho
PH12018550008A1 (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
EP3964520A4 (fr) Nouvel oligopeptide et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif
PH12020500532A1 (en) Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin
EP3795170A4 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne
EP3895719A4 (fr) Composition pharmaceutique comprenant un lactobacillus sakei wikim30 comme principe actif pour la prévention ou le traitement d'un cancer
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17874184

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17874184

Country of ref document: EP

Kind code of ref document: A2